This site is intended for US residents.
  • REGISTER
  • Important Safety
    Information
  • Prescribing
    Information
  • For Healthcare
    Professionals
  • Español
Jivi® antihemophilic factor (recombinant), PEGylated-aucl Logo
SELECTED IMPORTANT SAFETY INFORMATION: You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi. CONTINUE READING BELOW
Bayer Logo
SELECTED IMPORTANT SAFETY INFORMATION: You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi. CONTINUE READING BELOW
Bayer Logo Jivi Logo
  • GET TO KNOW JIVI
  • Pharmacokinetics (PK)
  • Understanding PK
  • PK Studies
  • Getting Started With Jivi
  • Co-Pay & SUPPORT Programs
  • Patient/Caregiver
    Speaker Programs
  • Find Your Bayer Rep
    • GET TO KNOW JIVI
    • Pharmacokinetics
      (PK)
      • Understanding PK
      • PK Studies
    • Getting Started With
      Jivi
    • Co-Pay & SUPPORT
      Programs
    • Patient/Caregiver Speaker Programs
    • Find Your Bayer Rep
    The extended-half-life rFVIII
    with proven protection,
    safety and unique
    step-wise dosing1,2,3,4

    FEEL EMPOWERED
    to step up to the challenge
    with Jivi®

    Get to
    Know Jivi®
    Explore bleed rates, safety,
    every-5-day and twice-weekly
    dosing from the main Jivi clinical
    study and extension study.
    Head-to-Head
    PK Comparison
    Read about how the activity
    of Jivi® in the body compares
    with Eloctate®.
    Jivi® Co-pay &
    Support Programs
    Learn how you may be able to
    save on your Jivi® prescription.
    My Journey
    to Jivi®
    Watch videos from real Jivi
    patients
    and caregivers and find
    an upcoming
    live or virtual
    speaking event near
    you.
    rFVIII, recombinant Factor VIII.

    INDICATIONS

    • Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
    • Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery. Jivi can reduce the number of bleeding episodes in adults and adolescents with hemophilia A when used regularly (prophylaxis).
    • Jivi is not for use in children below 12 years of age or in previously untreated patients.
    • Jivi is not used to treat von Willebrand disease.

    IMPORTANT SAFETY INFORMATION

    • You should not use Jivi if you are allergic to rodents (like mice and hamsters) or to any ingredients in Jivi.
    • Tell your healthcare provider about all of your medical conditions that you have or had.
    • Tell your healthcare provider if you have been told that you have inhibitors to Factor VIII.
    • Allergic reactions may occur with Jivi. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, or nausea.
    • Allergic reactions to polyethylene glycol (PEG), a component of Jivi, are possible.
    • Your body can also make antibodies, called “inhibitors,” against Jivi, which may stop Jivi from working properly. Consult your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
    • If your bleeding is not being controlled with your usual dose of Jivi, consult your doctor immediately. You may have developed Factor VIII inhibitors or antibodies to PEG and your doctor may carry out tests to confirm this.
    • The common side effects of Jivi are headache, cough, nausea, and fever.
    • These are not all the possible side effects with Jivi. Tell your healthcare provider about any side effect that bothers you or that does not go away.
    • For additional important risk and use information, please see the full Prescribing Information.

    References: 1. Jivi® Prescribing Information. Whippany, NJ: Bayer LLC; 2018. 2. Data on file. Tx Review 0918. Bayer; 2018. 3. Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15(3):411-419. 4. Lalezari S et al. Haemophilia 2019;25:1011-1019

    • Prescribing Information
    • Privacy Policy
    • Conditions of Use
    • California Transparency in Supply Chains
    • Site Map
    • Contact Us

    You are encouraged to report side effects or quality complaints of prescription drugs to the FDA.
    Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    © 2020 Bayer. All rights reserved.
    All trademarks are the property of their respective owners.
    Access Services by Bayer is a trademark of Bayer.

    Site last modified 10/20

    Jivi® antihemophilic factor (recombinant), PEGylated-aucl Logo Bayer Logo

    Are you sure you want to leave the Jivi website?

    Bayer is not responsible for the content viewed on other websites.

    Yes No

    This site contains information on Jivi, which is not for use in patients less than 12 years of age or in previously untreated patients.

    OK